Improved Access to Affordable Medications Act

This bill amends rules to improve access to generic drugs and biosimilars by requiring brand-name drug manufacturers (license holders) to provide samples for development. It establishes a "designated delivery service" standard for overnight/2-day shipping and sets strict timelines: the FDA must respond to sample requests within 60 days for non-clinical testing or 120 days for clinical trials. Manufacturers must publicly post clear policies within 45 days of product approval, including contact details, request procedures, and responsible officers. These changes directly affect generic drug developers seeking samples and brand companies managing product access. The bill focuses on streamlining the sample request process to accelerate generic drug development without altering drug safety requirements.